Arrayit Corporation Logo

Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.  - Powerful Science for Life™

Corporate - Media & Press - Press Release

Arrayit Corporation and TeleChem International Inc Celebrate 25 Years in Business

By GlobeNewswire, November 1, 2018, 05:30:00 AM EDT: Source Arrayit Corporation

Sunnyvale, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that management and staff are commemorating its 25-year business anniversary. On November 1, 1993, with two telephones and seed capital borrowed from their parents, entrepreneurs Rene Schena and Todd Martinsky founded industrial and specialty chemicals manufacturing and wholesale distribution company TeleChem International, Inc in downtown San Jose, California. After adding the microarray life sciences segment in 1997, TeleChem International grew to become the 11th largest woman-owned business enterprise in Silicon Valley, and joined the elite Inc 500 list of fastest-growing private companies in the United States in 2002 and 2003. Arrayit Corporation became publicly traded in 2009, making the chemicals division a wholly-owned subsidiary. Today, Arrayit leverages its life sciences and clinical expertise to commercialize healthcare tests for allergy, dietary wellness, food safety and pipeline indications for ovarian cancer and Parkinson’s Disease.

Arrayit recently completed an allergy testing pilot program for a top retail chain, established a nationwide network of 1,700 allergy sales professionals, met with top officials at the United States Food and Drug Administration (FDA) regarding approval of a major product line, signed allergy testing contracts with a consortium of 178 medical clinics, received approval for in-store promotions by a major retailer, announced allergy testing partnerships with major allergy therapeutics providers, received approval for direct Medicare billing by the Centers for Medicare and Medicaid Services (CMS), reported the sale and shipping of clinical instrumentation to the FDA, aced three consecutive rounds of proficiency testing with the College of American Pathologists, and launched the Patient Data Solutions allergy portal for doctors and clinics. The company’s breadth and depth of experience and advanced microarray technology provide the foundation on which these major new initiatives are being implemented.

Chief Executive Officer Rene Schena states, “This 25-year milestone is a testament to our loyal customer base and trusted suppliers around the world. We are very proud of our employees and their entrepreneurial spirit. We wish to take this opportunity to reflect upon our accomplishments, celebrate our successes to date, and thank all of our shareholders and colleagues for their kind support as we embrace the future.”

About Arrayit
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve wellness and human health. Please visit www.arrayit.com for more information.

Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's public filings.

CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com

 

 

 

Copyright 1993-2018 Arrayit Corporation. All rights reserved.